The American Journal of Managed Care3d
Real-World Data: Acalabrutinib Safety Profile Superior in CLL/SLL
A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib ...
FierceBiotech3d
InnoCare's TYK2 inhibitor shows potential to rival Sotyktu in Chinese phase 2 psoriasis trial
InnoCare Pharma’s tyrosine kinase 2 (TYK2) inhibitor has hit the main goals of a phase 2 trial in China, sustaining the ...
Innovent and ASK Pharm to commercialise limertinib for lung cancer
"Innovent and ASK Pharm to commercialise limertinib for lung cancer" was originally created and published by Pharmaceutical ...
manilatimes4d
Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
BioAtla: Numerous Catalysts Coming In Q4
BioAtla, Inc. faces financial challenges but presents promising pipeline projects in cancer treatment, offering opportunities ...